In addition, inter-assay comparisons of antibody performance between CyCIF and IHC (Fig. 3, Supplementary Fig. 4) and between CyCIF and HER2 FISH (in HER2-positive breast tumors) was performed to provide orthogonal qualification (Fig. 3). This evidence concerns the gene ERBB2 and breast neoplasm.